Therefore, Lrig1 on the surface of CD4+ T cells is important for the suppressive population of Th17 and Treg cells in mice and humans, and Lrig1-targeting mAb or adoptive transfer of Lrig1+ T cells can be new therapeutics for treating autoimmune diseases by targeting or regulating the immune-suppressive T cells. This evidence concerns the gene LRIG1 and autoimmune disease.